May 18th 2024
A biologics license application has been accepted by the FDA for subcutaneous nivolumab to treat adult patients eligible for approved solid tumor nivolumab indications
January 29th 2024
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
January 18th 2023A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.